Table 3 Children’s Oncology Group chemotherapy regimens

From: Updated favourable-histology Wilms tumour risk stratification: rationale for future Children’s Oncology Group clinical trials

Name

Chemotherapeutic agents

Duration

EE-4A

Vincristine, dactinomycin

19 weeks

DD-4A

Vincristine, dactinomycin, doxorubicin (cumulative doxorubicin, 150 mg/m2)

25 weeks

VADa

Vincristine, dactinomycin, doxorubicin (35 mg/m2 per cycle)

6–12 weeks

Regimen I

Vincristine, doxorubicin (cumulative 225 mg/m2), cyclophosphamide (cumulative 15.4 g/m2), etoposide (cumulative 2,000 mg/m2)

25 weeks

Regimen M

Vincristine, dactinomycin, doxorubicin (cumulative 195 mg/m2), cyclophosphamide (cumulative 8.8 g/m2), etoposide (cumulative 2,000 mg/m2)

31 weeks

  1. aVAD is a pre-resection regimen used only in patients with bilateral Wilms tumour, Wilms tumour in a solitary kidney or unilateral Wilms tumour in a patient predisposed to the development of bilateral Wilms tumours (such as those with a predisposition syndrome or multicentric Wilms tumour).
Back to article page